Cohen M B, Hawkins J A, Weckbach L S, Staneck J L, Levine M M, Heck J E
Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, Ohio 45229.
J Clin Microbiol. 1993 Feb;31(2):351-3. doi: 10.1128/jcm.31.2.351-353.1993.
Enteroaggregative Escherichia coli (EAggEC) has been found to be associated with pediatric diarrhea in developing countries. In order to determine the role of EAggEC as an agent of traveler's diarrhea, we used a sensitive and specific DNA probe for EAggEC to screen bacterial colony blots from 278 volunteers before and after travel. Colonization with EAggEC was infrequent (2.5%) prior to travel but rose to 27 to 33% after travel in volunteers who took either placebo or trimethoprim-sulfamethoxazole. Travelers who took trimethoprimsulfamethoxazole were colonized with organisms that were uniformly resistant to that antimicrobial agent; when volunteers received ciprofloxacin, colonization with EAggEC was prevented (2.0%). Although colonization rates were high in the placebo and trimethoprim-sulfamethoxazole groups, only a minority of travelers who were colonized with EAggEC experienced diarrhea. On the basis of our data, we suggest that colonization with EAggEC alone is not sufficient to cause traveler's diarrhea.
肠集聚性大肠杆菌(EAggEC)已被发现与发展中国家的小儿腹泻有关。为了确定EAggEC作为旅行者腹泻病原体的作用,我们使用了一种针对EAggEC的灵敏且特异的DNA探针,对278名志愿者旅行前后的细菌菌落印迹进行筛选。旅行前EAggEC的定植情况不常见(2.5%),但在服用安慰剂或甲氧苄啶 - 磺胺甲恶唑的志愿者中,旅行后定植率升至27%至33%。服用甲氧苄啶 - 磺胺甲恶唑的旅行者被对该抗菌药物具有一致耐药性的生物体定植;当志愿者接受环丙沙星时,EAggEC的定植得到预防(2.0%)。尽管安慰剂组和甲氧苄啶 - 磺胺甲恶唑组的定植率很高,但只有少数被EAggEC定植的旅行者出现腹泻。根据我们的数据,我们认为仅EAggEC定植不足以导致旅行者腹泻。